How did GlaxoSmithKline (GSK) do in the second quarter of 2021?

GlaxoSmithKline (LSE:GSK) released its second quarter of 2021 results today. The GSK share price went up, then it fell back down. Read why here.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE:GSK) reported strong sales but a slight dip in profits in its second-quarter (Q2) of 2021 report released today. Sales grew 6% (or 15% on a constant exchange rate basis) compared to the Q2 of 2020. The growth in revenue was mainly the result of robust growth — up 39% for this quarter — in the vaccines business. 

However, reported earnings per share (EPS) came in at 27.9p for Q2 2021. That is 39% lower than the 45.5p reported for Q2 2020. GSK also reports adjusted EPS. On this basis, Q2 2021 EPS come in at 28.1p, beating the 19.2p for Q2 2020. Adjusted EPS numbers might provide a better basis for comparisons and assessment as it strips out exceptional and one-time items, like disposals, which elevated Q2 2020 reported EPS.

GSK dividend and earnings outlook for 2021

Pipeline milestones achieved in Q2 2021 included positive phase III results for a drug to treat anaemia associated with chronic kidney disease and the US drug regulator competing review of an HIV drug. GSK announced three strategic collaborations across immuno-oncology and neurology, HIV treatment in Q2 2021. A phase III trial to see if a Covid-19 vaccine that uses GSK’s adjuvant technology was also started in the second quarter.

Overall, Q2 2021 is viewed as positive for GSK. Company management is confident about hitting the upper range of its adjusted EPS targets for 2021. However, that target is for a mid-to-high single-digit per cent decline in adjusted EPS on a constant exchange rate basis. But, that target looks a bit better than the double-digit declines suggested not too long ago. 

GSK has declared a dividend of 19p per share for Q2 2021. A total 2021 dividend of 80p per share, which is the same as last year, is expected. But dividends are expected to fall to 55p in 2022 when the company splits into New GSK (paying 44p) and a consumer healthcare company (paying 11p).

How have investors reacted to the GSK Q2 2021 report?

GSK’s Q2 2021 report was released at 12:00 pm BST. Initially, investors seemed happy, as the GSK share price lept by almost 100p. But, just after 12:15 pm BST, the GSK stock price started to give back all of its gains. Right now, the GSK share price is back where it was at the start of the day, sitting around 1,398p.

Based only on the share price moves, I would say that investors were unmoved by the Q2 2021 results. On the one hand, there is the expectation of full-year 2021 adjusted EPS falling — which usually bodes ill for a share price — and the looming dividend cut. But on the other hand, the Q2 2021 results suggest that things are starting to turn around.

GSK management stressed that the pandemic has been tough. Health conditions other than Covid-19 have been somewhat neglected, leading to lower sales for GSK medicines. Analysts were expecting 19.9p of adjusted EPS, and GSK beat expectations comfortably for Q2 2021. The earnings beat was probably the headline that grabbed traders’ attention and drove the share price higher initially. However, after reading further into the report, perhaps they decided that nothing much had changed. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie owns shares in GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black woman using a mobile phone in a transport facility
Investing Articles

After soaring 35% this year, is there still value in Barclays shares? Here’s what the charts say!

Barclays has been on a tear in 2024. But where does that leave investors considering buying some shares now? This…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

Nvidia stock has surged 3,450%. This UK investment trust owns loads!

Nvidia's recent amazing price surge has helped boost the value of this investment trust too as the chipmaker is its…

Read more »

Bronze bull and bear figurines
Investing Articles

After the general election what might happen to the FTSE 100?

Our writer’s been looking at the manifestos of the three main political parties to try and understand how the general…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

When will Shein hit the UK stock market and should I invest?

With Shein looking likely to list on the London stock market in 2024, this writer weighs up the case for…

Read more »

Investing Articles

Start supercharging passive income with REITs!

Are REITs the ultimate investment for boosting income generated from a portfolio? Zaven Boyrazian explores some of the most lucrative…

Read more »

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »